OKYO Pharma Limited Sponsored ADR OKYO
1.38
0.00
0.00%
as of 25 Sep
- Market cap
- $72.4M
- P/E
- 0.0×
Follow OKYO
Insider Buys
alert about insiders buying in the last 12 month
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.43 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.80 | 1.78 |
Net Debt/EBITDA |
2.42 | 0.22 | 0.05 | 0.14 | 0.43 | 2.02 | 0.13 | 0.13 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 42.57% | 0.00% | 1.39% | 5.29% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (1.08) | 0.00 | 0.02 | (0.23) | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.66 | 0.38 | 0.56 | 0.58 | 1.01 | 0.48 | 0.88 | 0.41 |
Capex/Depreciation |
(3.39) | (0.46) | 0.00 | (1.55) | (0.74) | (4.60) | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (263.79%) | 82.36% | 424.20% | (2,968.40%) | (131.39%) | (129.50%) | (1,600.62%) | 0.00% | |
| (72.60%) | (180.37%) | (498.89%) | (279.27%) | (95.35%) | (87.22%) | (227.14%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,575.19%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(72.55%) | 84.80% | 286.17% | 646.36% | (184.26%) | (63.45%) | 1,357.57% | (1,482.57%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.16) | (0.05) | (0.32) | (0.35) | (0.36) | (0.31) | 0.00 | 0.00 |
Cash per Share |
0.55 | 0.04 | 0.03 | 0.18 | 0.18 | 1.34 | 0.00 | 0.00 |
Shareholders Equity per Share |
0.33 | (0.14) | (0.20) | (0.09) | 0.20 | 1.03 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.33 | (0.14) | (0.20) | (0.09) | 0.20 | 1.03 | 0.00 | 0.00 |
Free Cash Flow |
(5.94) | (1.81) | (9.49) | (7.70) | (5.47) | (1.61) | (1.35) | (2.00) |
Working Capital |
12.33 | (5.55) | (5.88) | (2.06) | 2.94 | 5.28 | (0.14) | 0.33 |
Capital Expenditures |
(0.01) | 0.00 | — | (0.01) | 0.00 | (0.01) | — | 0.00 |
Net Current Asset Value |
12.33 | (5.55) | (5.88) | (2.06) | 2.94 | 5.21 | (0.17) | 0.33 |
| Other line items | ||||||||
Quick Ratio |
2.43 | 0.40 | 0.21 | 0.72 | 3.17 | 4.09 | 0.79 | 1.73 |
Depreciation/Fixed assets |
0.29 | 1.30 | 1.15 | 0.53 | 0.44 | 0.25 | 0.20 | 0.18 |
Cash ROIC |
(18.05%) | 45.45% | 187.89% | (183.07%) | (96.91%) | (13.05%) | (1,088.75%) | (208.72%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.16) | (0.05) | (0.32) | (0.35) | (0.36) | (0.31) | 0.00 | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.25 | 1.41 | 0.93 | 1.37 | 0.85 | 0.21 | 0.22 | — |
Average Payables |
8.50 | 7.71 | 5.66 | 2.78 | 1.49 | — | — | — |
Average Assets |
12.33 | 2.61 | 3.37 | 4.75 | 5.70 | 3.85 | 0.68 | — |
Average Common Equity |
3.39 | (5.71) | (3.97) | 0.45 | 4.13 | 2.59 | 0.10 | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates